JPWO2020257665A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257665A5 JPWO2020257665A5 JP2021575509A JP2021575509A JPWO2020257665A5 JP WO2020257665 A5 JPWO2020257665 A5 JP WO2020257665A5 JP 2021575509 A JP2021575509 A JP 2021575509A JP 2021575509 A JP2021575509 A JP 2021575509A JP WO2020257665 A5 JPWO2020257665 A5 JP WO2020257665A5
- Authority
- JP
- Japan
- Prior art keywords
- azacytidine
- pharmaceutical composition
- days
- therapeutic agent
- additional therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 35
- 229960002756 azacitidine Drugs 0.000 claims 35
- 239000003814 drug Substances 0.000 claims 25
- 229940124597 therapeutic agent Drugs 0.000 claims 25
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 8
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 claims 2
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 claims 2
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 2
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims 2
- 229950006304 gilteritinib Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 2
- 229950010895 midostaurin Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 2
- 229960001183 venetoclax Drugs 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 230000019522 cellular metabolic process Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 1
- 229950010133 enasidenib Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 claims 1
- 229950010738 ivosidenib Drugs 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims 1
- 229950001626 quizartinib Drugs 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| US62/864,413 | 2019-06-20 | ||
| PCT/US2020/038760 WO2020257665A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537384A JP2022537384A (ja) | 2022-08-25 |
| JP2022537384A5 JP2022537384A5 (https=) | 2023-06-08 |
| JPWO2020257665A5 true JPWO2020257665A5 (https=) | 2023-06-08 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| JP2021575509A Pending JP2022537384A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12447171B2 (https=) |
| EP (2) | EP3986403A1 (https=) |
| JP (2) | JP2022537551A (https=) |
| KR (2) | KR20220050874A (https=) |
| CN (2) | CN114727996A (https=) |
| AU (2) | AU2020296179A1 (https=) |
| BR (2) | BR112021025537A2 (https=) |
| CA (2) | CA3143719A1 (https=) |
| IL (2) | IL289110A (https=) |
| MX (2) | MX2021015993A (https=) |
| WO (2) | WO2020257665A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| EA201891317A3 (ru) | 2015-11-30 | 2019-04-30 | Дьюк Юниверсити | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2018017754A1 (en) | 2016-07-19 | 2018-01-25 | Duke University | Therapeutic applications of cpf1-based genome editing |
| WO2019144061A1 (en) | 2018-01-19 | 2019-07-25 | Duke University | Genome engineering with crispr-cas systems in eukaryotes |
| US20240141341A1 (en) * | 2021-03-01 | 2024-05-02 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| WO2022215995A1 (ko) * | 2021-04-05 | 2022-10-13 | 주식회사 피노바이오 | 4'-티오-5-아자-2'-디옥시사이티딘 및 베네토클락스의 병용 요법 |
| JP2024517318A (ja) * | 2021-05-11 | 2024-04-19 | アッヴィ・インコーポレイテッド | アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
| CN117651556A (zh) * | 2021-05-11 | 2024-03-05 | 艾伯维公司 | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 |
| US20250312327A1 (en) * | 2021-10-14 | 2025-10-09 | Pharos Ibio Co., Ltd | Composition for combination therapy, comprising 2,3,5-substituted thiophene compound |
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782612B1 (en) * | 2008-05-15 | 2023-11-08 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| EA201790376A1 (ru) | 2014-09-05 | 2017-08-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| WO2016040238A1 (en) | 2014-09-08 | 2016-03-17 | Celgene Corporation | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| EP3371152B1 (en) | 2015-11-05 | 2020-12-23 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
| CN109462980B (zh) * | 2016-03-15 | 2022-02-08 | 奥莱松基因组股份有限公司 | 用于治疗血液恶性肿瘤的lsd1抑制剂的组合 |
| US20200069677A1 (en) * | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| WO2019012328A1 (en) | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2020
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
-
2021
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020257665A5 (https=) | ||
| JP2025142338A5 (https=) | ||
| JP2021066744A5 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| JP2025092508A5 (https=) | ||
| JP2018193377A5 (https=) | ||
| MXPA05004395A (es) | Composiciones de milnacipran de liberacion modificada. | |
| HRP20230696T1 (hr) | Liječenje hereditarnog angioedema | |
| JP2006516571A5 (https=) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2012502047A5 (https=) | ||
| EP3691621B1 (en) | Neupanex ®: neuroprotective, neuroregenerational,&neurogenesis supporting supplement combination | |
| JP2020500864A5 (https=) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| Uddin et al. | Applications of Metformin in Dentistry—A review | |
| JPWO2020257671A5 (https=) | ||
| WO2006113853A2 (en) | Topiramate compositions for treatment of headache | |
| JP2014507475A5 (https=) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| CN1279582A (zh) | 用于口服的含血清素配方及其使用方法 | |
| Bratel et al. | The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial. | |
| CA2721728A1 (en) | Treatment of inflammatory bowel disease with 6-mercaptopurine | |
| Toyofuku | Efficacy of milnacipran for glossodynia patients | |
| CN1703244A (zh) | Ppar配体和抗氧剂间的联合及其用于治疗肥胖的用途 | |
| JP2005503391A5 (https=) | ||
| JP6184960B2 (ja) | メラトニンの新規用途 |